Skip to content
Search

Latest Stories

RPS unhappy over delay to enact HRT prepayment scheme

The Royal Pharmaceutical Society has expressed its disappointment over the recent announcement by pharmacy minister Maria Caulfield postponing the prepayment scheme for Hormone Replacement Therapy (HRT).

In October 2021, the government announced that women in England would only have to pay one charge of £18.70 for up to a 12-month supply of hormone replacement therapy (HRT). Caulfield recently confirmed that the move would not be enacted until April 2023.


RPS previously called for a reduction in inequalities in women’s health, including access and availability to medicines.

Thorrun Govind, chair of RPS in England, responded: “This is disappointing news. Delaying this move will frustrate many who already pay for monthly HRT prescriptions and will further drive health inequalities already experienced by women across the country.

“Women experiencing the menopause need support to stay well and remain in the workplace. For some, HRT prescriptions are an essential part of this but also a financial drain during a cost of living crisis.

“We believe everyone should have access to the medicines they need, regardless of ability to pay, and will continue to call on the Government to scrap prescription charges in England altogether.”

Prescriptions for HRT have more than doubled in England over the past five years, from 238,000 in January 2017 to almost 538,000 in December 2021.

More For You

First daily pill for endometriosis to be available on NHS

Instead of travelling to clinics for injections, endometriosis patients can take a daily tablet at home

Getty Images

New endometriosis pill approved for NHS use, but only few patients will benefit

The National Institute for Health and Care Excellence (NICE) has approved a new pill for the treatment of endometriosis, providing hope for thousands of women affected by the debilitating condition.

The pill, called relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), is the first long-term daily pill approved for use in the UK to treat endometriosis, and it is expected to help about 1,000 patients every year.

Keep ReadingShow less
​RPS urges its members and fellows to vote in favour of Royal College for “a stronger, louder voice”

The Special Resolution Vote will remain open until 5 p.m. on Thursday, 24 March 2025.

Getty Images

Royal College voting begins: A historic moment in the profession’s evolution

Becoming a royal college will ensure pharmacy profession gains the recognition and authority it deserves, says RPS president Professor Claire Anderson.

Starting today (13), members and fellows of the Royal Pharmaceutical Society (RPS) will begin voting on the proposed changes to its Royal Charter, marking the beginning of a historic shift toward becoming the Royal College of Pharmacy.

Keep ReadingShow less
GPs to play crucial role in transforming Wales’ health service

Jeremy Miles

(Photo credit: www.gov.wales )

Strengthening GPs’ role key to transforming healthcare - Jeremy Miles

Welsh health secretary Jeremy Miles has recognised the need to transform health services and bring healthcare closer to home.

Speaking at the recent Welsh Local Medical Committees Conference, he emphasised that strengthening the role of GPs would be crucial in improving patient healthcare and tackling NHS waiting lists.

Keep ReadingShow less
NPA and IPA urge NHS England to release pharmacy economic analysis immediately

Pharmacy bodies call for transparency on the funding gap amid ongoing contract negotiations.

Getty Images

Pharmacy bodies demand immediate release of economic analysis

The National Pharmacy Association (NPA) and the Independent Pharmacies Association (IPA) have jointly written to NHS England, demanding the immediate release of the independent economic analysis of pharmacy finances commissioned last autumn.

An open letter, signed by the owners of 3,034 pharmacies in England, calls for transparency on the funding gap amid ongoing contract negotiations.

Keep ReadingShow less